Blog
RSS FeedPosted by Michael Wonder on 02 Feb 2022
Register study on gene therapy with Zolgensma starts
1 February 2022 - Experience from clinical practice with Zolgensma, a gene therapy against certain forms of spinal muscular atrophy in ...
Posted by Michael Wonder on 25 Jan 2020
Registry-data – of sufficient quality – are suitable for the extended benefit assessment of drugs
24 January 2020 - Rapid report shows how routine practice data should be collected and processed. ...